Provided is a functionalized polymer useful for extracting, isolating, and/or purifying membrane proteins with their native protein structures being retained. Also provided are a Native Cell Membrane Nanoparticle (NCMN) system which contains the above functionalized polymer and a membrane protein and a method to characterize and/assess the native structure of the membrane protein.
C08F 228/02 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison au soufre ou par un hétérocycle contenant du soufre par une liaison au soufre
Aerosolization devices and procedures are disclosed which provide enhancement to air-jet and other dry powder inhaler (DPI) technologies to improve and optimize aerosolization performance and expand dose loading capabilities. An exemplary device includes, for example, an aerosolization chamber which has a variable chamber size and an adjustment mechanism configured to adjust the chamber size between actuations. In use, a distance between an air-jet pathway of the aerosolization chamber and a top of the powder bed is substantially maintained even as the powder is emptied over the successive device actuations.
A61M 11/02 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression d'air sur les liquides à pulvériser ou vaporiser
3.
TARGETED ERADICATION OF EBV-POSITIVE CELLS BY CRISPR/CAS-MEDIATED EBV REACTIVATION
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A method of preparing epinephrine or norepinephrine is provided. The method includes reacting a starting material comprising 2-chloro-l-(3,4-dihydroxyphenyl)ethan-l- one with an amine nucleophile RNH2 (R=H for the synthesis of epinephrine or Me for the synthesis of norepinephrine) under conditions suitable for nucleophilic substitution of the starting material to form a substituted starting material and reacting the substituted starting material with a tethered ligand transition metal catalyst under conditions suitable for transfer¬ hydrogenation to produce epinephrine or norepinephrine.
C07C 215/46 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné
C07C 215/56 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées qui sont substituées de plus par des groupes hydroxy
C07C 213/00 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné
C07C 215/58 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées qui sont substituées de plus par des groupes hydroxy avec des groupes hydroxy et le cycle aromatique à six chaînons, ou le système cyclique condensé contenant ce cycle, liés au même atome de carbone de la chaîne carbonée
Methods for the preparation of asymmetrically reduced compounds such as (R)- phenylephrine and (R)- salbutamol) are provided. The methods comprise two steps: 1) nucleophilic substitution of a halogenated starting material to form an unprotected amino ketone, followed by 2) asymmetric transfer hydrogenation of the unprotected amino ketone. The methods are advantageously performed under mild conditions, e.g. at ambient pressure.
C07C 213/02 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions impliquant la formation de groupes amino à partir de composés contenant des groupes hydroxy ou des groupes hydroxy éthérifiés ou estérifiés
C07C 225/06 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant saturé et acyclique
C07C 225/04 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant saturé
Bio-artificial blood substitutes are provided for intravenous medical use to restore or increase tissue perfusion and oxygen delivery in a pre-hospital or hospital setting. The bio-artificial blood substitutes comprise three modular components (polyethylene glycol (PEG) polymers to increase perfusion, a hemoglobin-based oxygen carrier (HBOC) plus L-arginine to prove oxygen carrying capacity, and a lyophilized fibrinogen or plasma component to provide hemostasis potential, all of which are administered sequentially in modules to treat low perfusion states with possible coagulopathy as seen in blood loss and shock. The three solutions are stable at ambient temperature and are well-suited for use in the field, e.g., when immediate, critical care is needed such as on the battlefield, during natural disasters or other mass casualty events. Other use may include clinical need for transfusion or for peri-surgical resuscitation in patients unable to receive standard blood products.
Methods of detecting cysteine-containing peptides are provided. The methods include steps of contacting a resistive-pulse nanopore sensing system with a sample containing cysteine-containing peptides of at least 10 amino acid residues in length, wherein the resistive-pulse nanopore sensing system comprises thiolate-capped gold clusters arranged in a cis side of nanopores and detecting a change in current indicative of exchange between a cysteine-containing peptide and the thiolate-capped gold clusters.
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
8.
DEVICES AND METHODS FOR REPAIRING DAMAGE TO A TISSUE
An example device for repairing a tissue is described herein. The device can include a flexible carrier layer, and a support member including a plurality of micro-protrusions extending therefrom. The support member can be at least partially integrated with the flexible carrier layer. Additionally, the flexible carrier layer can be configured to cover at least a portion of the tissue, and the micro-protrusions can be configured to mechanically interface with the tissue.
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/24 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci
A61B 5/388 - Études de la conduction nerveuse, p. ex. détection du potentiel d’action d’un nerf périphérique
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
9.
SUSTAINED RELEASE FORMULATIONS AND METHODS OF USE THEREOF
A method of delivering an active ingredient to a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a formulation comprising biodegradable, polymeric microparticles and an active ingredient selected from the group consisting of levo-alpha-acetylmethadol (LAAM), nor-LAAM, and dinor-LAAM, wherein the active ingredient is part of a hydrophobic ion-pairing (HIP) complex and wherein the HIP complex is associated with the microparticles. Sustained release formulations containing an active ingredient are also provided.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Methods for treating liver cancer in a patient are provided. The methods include steps of administering at least one dose of a therapeutically effective amount of a composition comprising indocyanine green (ICG) and applying a PDT light source to the liver of the patient, wherein the PDT light source comprises a transarterial fiber optic coaxial catheter comprising a laser light, a sheet having an array of light-emitting diode (LED) lights, or a micro-injectable LED implant configured for delivery inside the liver, wherein the PDT light source is applied for a time period sufficient to release reactive oxygen species from the photosensitizing agent and induce apoptosis of cancer cells. A PDT system may include a composition comprising ICG and a PDT device comprising at least one light source enabled for application of light to a target tumor.
A series of non-peptide mu opioid receptor (MOR) selective modulators is provided. The compounds have the general formula (I) where R is (II) and where one of a, b, c, d, e or f is the point of attachment of indole ring R to the epoxymorphinan skeleton; at least one of the atoms at positions a, b, c, d, e and f is N; the remaining atoms at positions at a, b, c, d, e and f are CH; and * is a chiral carbon. The compounds are generally MOR antagonists and are used to treat disorders related to opioid receptor functions such as opioid addiction and opioid overdose, for the treatment of neurological diseases and for the treatment of pain, without causing constipation.
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
12.
METHODS FOR DECELLULARIZING ANIMAL TISSUE AND BIOINKS DERIVED THEREFROM
A method of decellularizing in an animal tissue includes digesting the animal tissue; treating the animal tissue with a surfactant: treating the animal tissue with at least one zwitterionic detergent to form a decellularized animal tissue; and treating the decellularized animal tissue with at least one advanced glycation end-product (AGE) inhibitor to reduce AGE crosslinking in the decellularized animal tissue. The decellularized animal tissue may be ground into a powder and dissolved in a digest solution to form a bioink composition useful for 3D printing an in vitro model of healthy or diseased tissue.
Provided is a functionalized polymer useful for extracting, isolating, and/or purifying membrane proteins with their native protein structures being retained. Also provided are a Native Cell Membrane Nanoparticle (NCMN) system which contains the above functionalized polymer and a membrane protein and a method to characterize and/assess the native structure of the membrane protein.
C08G 81/02 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p. ex. polymères séquencés au moins un des polymères étant obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carbone
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
14.
FIRE-RESISTANT, FIRE RETARDANT AND/OR THERMAL INSULATION
An open cell foam, and particularly aerogels or other foams, having an inorganic, hydraded phase change material (PCM) embedded within pores or cells or a network within the foam have fire retardant, fire resistant and thermal insulating properties. These composite materials are preferably monolithic in character, and are mechanically robust allowing for example the attachment of nails or screws. With the PCM distributed throughout the open cell foam, the composite material has a wide array of applications including providing thermal, fire resistant, and fire retardant uses in battery containers, in automotives and other vehicles, etc.
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p. ex. par séchage du coagulum
C09K 5/14 - Substances solides, p. ex. pulvérulentes ou granuleuses
F16L 59/02 - Forme ou configuration de matériaux isolants, avec ou sans revêtement formant un tout avec les matériaux isolants
15.
ELASTOMERIC SILK FIBROIN AND METHODS OF MAKING THE SAME
An elastomeric material which combines fibroin and siloxane exhibits high strength and flexibility while simultaneously being suitable for applications requiring biodegradability or cytocompatibility. An exemplary material is made from a combination of photocurable precursors - a photocurable fibroin and a photocurable siloxane. Hexafluoroisopropanol is used as a co-solvent with photocurable fibroin and photocurable polysiloxane. A cured film or coating is usable in dry and wet conditions. Various organic and/or electronic materials may be patterned on exemplary materials using techniques such as photolithography and screen printing.
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A neonatal circumcision training model serves as a life-like penis model on which medical practitioners may train in circumcision procedures. An exemplary model includes simulants of glans and shaft of the penis covered by a fascia-analog layer and a skin-analog layer. The layers are distinct and separable from one another and facilitate training medical professionals to spot the facia layer and distinguish it from the skin layer.
Provided herein are compounds and pharmaceutical compositions for treating cancer (e.g., melanoma), and methods of use thereof. The compounds disclosed herein inhibit MDA-9/Syntenin by binding both MDA-9/Syntenin PDZ domains.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
The technology is based on a conducting, ferromagnetic ink made from, in an aqueous suspension: conducting nanopolymers, ferromagnetic nanoparticles, an adhesion promoter and optionally, a surfactant and/or stabilizer. The ink is used to form reversible physical and electrical connections between e.g., rigid and flexible devices. In some aspects, the conducting nanopolymers are PEDOT:PSS (poly(3,4-ethylenedioxythiophene) polystyrene sulfonate) nanopolymers and the magnetic nanoparticles are iron oxide nanoparticles. The ink, which may be magnetic, is used to form solid, flexible, ferromagnetic conducting designs or nodes which may also be magnetic. The flexible, ferromagnetic conducting designs or nodes are used to form reversible magnetic electrical connections with devices such as potentiostats and data telemetry devices.
C09D 11/037 - Encres d’imprimerie caractérisées par des particularités autres que la nature chimique du liant caractérisées par le pigment
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
19.
FUSION PROTEINS OF IL-24 AND IMMUNOSTIMULATORY CYTOKINES, NK CELLS EXPRESSING IL-24 OR FUSION PROTEINS, AND METHODS OF USE THEREOF
The present disclosure provides fusion proteins of IL-24 with immunostimulatory cytokines and natural killer (NK) cells genetically engineered to express IL-24 or such fusion proteins, and methods of using these proteins and cells.
Sanford Burnham Prebys Medical Discovery Institute (USA)
Inventeur(s)
Fisher, Paul B.
Pellecchia, Maurizio
Das, Swadesh K.
Kegelman, Timothy P.
Wu, Bainan
De, Surya K.
Wei, Jun
Menezes, Mitchell E.
Emdad, Luni
Abrégé
Provided herein are, inter alia, compositions that bind to a PDZI domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.
A robotic gripper is capable of withstanding the high temperatures of processes such as metal additive manufacturing. One or more of the fingers of the gripper include a casted ceramic insulator with a steel finger backing. Industrial thermocouples may attach to a finger for active temperature monitoring. An exemplary robotic gripper is adaptive, usable on a collaborative robot, and temperature resistant to over 1000° C. without introducing costly augmentations such as liquid cooling.
Provided herein is a magnetic tunnel junction (MTJ) based non-volatile non-binary matrix multiplier comprising a straintronic MTJ “multiplier” and a spin-orbit torque driven MTJ “accumulator”. The multiplier quantity (one element of one matrix) and the multiplicand quantity (one element of the other matrix) are encoded in voltage pulses that are applied across two different sets of the straintronic MTJ terminals to produce a MTJ current output that is proportional to the product of the multiplier and multiplicand.
G06G 7/16 - Dispositions pour l'exécution d'opérations de calcul, p. ex. amplificateurs spécialement adaptés à cet effet pour la multiplication ou la division
G11C 11/16 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments dans lesquels l'effet d'emmagasinage est basé sur l'effet de spin
H10B 61/00 - Dispositifs de mémoire magnétique, p. ex. dispositifs RAM magnéto-résistifs [MRAM]
Mu opioid receptor (MOR) antagonists that specifically and effectively reverse the acute and chronic toxicity of fentanyl and its analogs are provided. The antagonists were developed by modifying the structural skeleton of fentanyl and/or phenylfentanil. The antagonists compete with fentanyls at the MOR binding site and when bound, they reverse the toxicity of fentanyls more effectively and selectively or specifically than naloxone, naltrexone, and other epoxymorphinan-type opioids.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 31/4747 - QuinoléinesIsoquinoléines condensées en spiro
Sputtering machines and substrate holders for such systems are described which include one or more magnets apart from the magnets typical of sputtering guns. The added magnets produce a magnetic field bias which is a new means for controlling depositional flux. ionization degree of a sputtered species. and microstructure properties of deposited coatings. An exemplary substrate holder may have a magnet or magnet array near or next to the surface supporting the substrate, and the magnet may assume multiple different magnetic field configurations depending on the desired properties of the resulting magnetic field bias within the reaction chamber.
Examples include an artificial conductive cilia based sensor having, on a substrate, a conductive pad and a neighbor conductive pad spaced in a direction. A first conductive cilium has a distal end, and a base end conductively secured to the conductive pad, and is particularly structured with bendability and elasticity. A second conductive cilium has a base end conductively secured to the neighbor conductive pad. A terminal is electrically connected to the conductive pad. Another terminal is electrically connected to the neighbor conductive pad. The first conducive cilium, in accordance with the bendability, is bent by a bending force directed in the spacing direction, to a bent state configured to establish a conductive path to the second conductive cilium and via the elasticity, to self-return to a relaxed state configured to terminate the conductive path.
G01F 1/54 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu en utilisant des effets mécaniques au moyen de chaînes, de bandes ou de fils flexibles introduits dans, et déplacés sous l’effet de, l’écoulement
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
VIRGINIA COMMONWEALTH UNIVERSITY (USA)
Inventeur(s)
Neuwelt, Alexander
Bryan, Allyn
Abrégé
The disclosure relates to compositions including acetaminophen or analogs thereof and CYP2E1 -inhibitors suitable for parenteral or oral administration. Methods of treating cancer in subjects by administering acetaminophen or analogs thereof and CYP2E1 -inhibitors are also included.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07D 231/14 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
Various embodiments of the present disclosure are directed to systems and methods of developing a self-optimizing regression model for identifying multiple analytes from complex mixtures. A system can perform a method of generating a model based at least in part on a plurality of calibration spectra; applying the model to at least one test spectrum corresponding to a test sample; and determining component concentrations of the test sample based at least in part on the application of the model.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 27/00 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
28.
MINI CIRCULAR RNA THERAPEUTICS AND VACCINES AND METHODS OF USE THEREOF
Synthetic mini circular RNA vaccine constructs are provided. The synthetic mini circular RNA constructs encode one or more antigens and are used, for example, as vaccines against cancer or infectious agents. In some aspects, the one or more antigens are translated as concatemer peptides by rolling cycle translation (RCT) of the mini circular RNA.
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
29.
POLYGENIC RISK ESTIMATOR FOR CERVICAL LENGTH CHANGE DURING PREGNANCY
A method for determining, for a woman, the risk of a premature short cervical length (sCL), and hence preterm birth, is provided. The method comprises measuring gene allelic variation in a biological sample obtained from the woman, developing a polygenic risk score (PRS), and identifying the woman as having an increased risk for sCL and preterm birth if the PRS is higher than that of corresponding standard controls. Methods for the prophylactic treatment of women identified as being at increased risk are also provided.
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Provided herein is a self-calibrating electrochemical sensor, which includes an indicator electrode, a reference electrode. and a calibration bridge that connects the indicator electrode and the reference electrode. The calibration bridge has an ion-conducting or electron-conducting phase that establishes a pre-measuring baseline electrochemical signal. When the sample to be tested is introduced to the sensor, the change in the electrochemical signal relative to the baseline is used to detect and/or quantify the analyte in the sample. The built-in calibration phase does not need to be removed when the sample is tested.
Anatomically accurate brain phantoms are physical models of brains which mimic the viscoelastic properties of brain tissues. The material used to represent different layers of the brain may be a composition of a hydrogel solution and a cross-linking agent, with ratios calculated and determined to accurately reflect the brain's mechanical properties, most notably, the viscoelasticity. Embedded sensors (e.g., accelerometers) measure impact forces and shear stresses/strains caused by a concussion-related experimental impact to the phantom. Uses of the hydrogel brain phantom include biomedical research and as a planning tool for medical treatments. A specific subject's brain may be replicated for designing personalized treatment.
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
Disclosed are various approaches for calculating crystal orientation via dark-field images from an electron microscope. In some examples, a system includes an electron microscope, at least one computing device comprising a processor and a memory, and machine-readable instructions stored in the memory. The instructions can cause the computing device to at least capture a plurality of dark-field images via the electron microscope. The computing device can calculate a crystal orientation based at least in part on data obtained from the dark-field images. The computing device can further generate an orientation map based at least in part on the crystal orientation.
G01N 23/20058 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffraction de la radiation par les matériaux, p. ex. pour rechercher la structure cristallineRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffusion de la radiation par les matériaux, p. ex. pour rechercher les matériaux non cristallinsRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux en mesurant la diffraction des électrons, p. ex. la diffraction d’électrons lents [LEED] ou la diffraction d’électrons de haute énergie en incidence rasante [RHEED]
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p. ex. la microscopie électronique à balayage [SEM]
H01J 37/28 - Microscopes électroniques ou ioniquesTubes à diffraction d'électrons ou d'ions avec faisceaux de balayage
34.
ENERGY EFFICIENT, STRAINED TOPOLOGICAL INSULATOR SPIN FIELD EFFECT TRANSISTOR (STI-SPINFET) FREQUENCY MULTIPLIER
A three-dimensional (3D) topological insulator (Tl), configured with a surface channel for conducting spin polarized electron flow, and piezoelectric element that strains the 3D Tl, responsive to an input voltage, producing stress in the surface channel according to a voltage- to-stress characteristic (VTSC). A spin polarizer and spin analyzer act as source and drain and produce an electric field through the surface channel when a voltage is applied between the source and drain, the spin polarizer injects spin polarized electrons to flow through the surface channel and arrive at the spin analyzer as arrival electrons. The surface channel has a stress-to-rotation characteristic (STRC) that, responsive to the stress, rotates the spin polarization such that the arrival electrons have a rotated plane of polarization, at a rotation angle.
H03B 19/00 - Production d'oscillations par multiplication ou division de la fréquence d'un signal issu d'une source séparée, n'utilisant pas de réaction positive
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
H01F 10/32 - Multicouches couplées par échange de spin, p. ex. superréseaux à structure nanométrique
A polymer-assisted 3D printing method and ink compositions are used to manufacture magnetocaloric devices having many applications including in heat pumps, refrigerators, etc. The ink compositions and printing methods can produce compositionally graded, anisotropically aligned magnetocaloric architectures with designed pores and channels, to bring forth significant improvement in heat exchange efficiency.
B22F 1/105 - Poudres métalliques contenant des agents lubrifiants ou liantsPoudres métalliques contenant des matières organiques contenant des agents lubrifiants ou liants inorganiques, p. ex. des sels métalliques
B22F 1/107 - Poudres métalliques contenant des agents lubrifiants ou liantsPoudres métalliques contenant des matières organiques contenant des matériaux organiques comportant des solvants, p. ex. pour la coulée en moule poreux ou absorbant
B22F 5/10 - Fabrication de pièces ou d'objets à partir de poudres métalliques caractérisée par la forme particulière du produit à réaliser d'articles avec des cavités ou des trous, non prévue dans les sous-groupes précédents
B22F 10/50 - Traitement des pièces ou des articles pendant leur formation, p. ex. traitements appliqués aux couches fusionnées pendant leur formation
B22F 10/60 - Traitement de pièces ou d'articles après leur formation
B33Y 40/20 - Posttraitement, p. ex. durcissement, revêtement ou polissage
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B33Y 80/00 - Produits obtenus par fabrication additive
H01F 1/01 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques
The present invention relates to compounds derived from 2-benzyloxyphenylethylamines of formula (I) and the pharmaceutically acceptable salts thereof. The invention also relates to the preparation of said compounds by means of a pathway that allows halogenated derivatives to be obtained. The obtained compounds exhibit biological inhibition activity on the human serotonin transporter (hSERT).
C07C 211/02 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné saturé acyclique
C07D 317/48 - Méthylènedioxybenzènes ou méthylènedioxybenzènes hydrogénés, non substitués sur l'hétérocycle
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Bivalent ligands which bind to MOR-CCR5 heterodimers are provided. The bivalent ligands comprise two discrete pharmacophores, naltrexone and maraviroc, linked by a spacer and bind to MOR-CCR5 heterodimers, e.g. at the surface of a cell. The bivalent ligands are useful in assays to detect MOR-CCR5 heterodimers, as therapeutic agents to prevent and/or treat diseases characterized by the presence of MOR-CCR5 heterodimers.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
38.
ULTRASONIC ELECTROSPINNING FOR THE PRODUCTION OF FINE AND ULTRAFINE FIBERS
Systems, devices, and methods employ advantages of ultrasonic vibration in the field of electrospinning. Fibers are produced from an ultrasonic nozzle exposed to an electric field established between the nozzle and a target object. Exemplary embodiments include electrospinning techniques that produce fine and ultrafine fibers in a high throughput via multiple jetting of spun solutions and melts. Ultrasonic vibration, in some instances combined with heating, reduces the voltage required for spinning. Vibrating power delivered to the nozzle may be selected so gas bubbles are generated by solvent cavitation in the spun solution. The bubbles are generated at the nozzle exit or else in such positions of the solution path so as to reach the nozzle exit where they further enhance multiple jetting of spun solutions.
An example device for repairing a tissue is described herein. The device can include a flexible carrier layer, and a support member including a plurality of micro-protrusions extending therefrom. The support member can be at least partially integrated with the flexible carrier layer. Additionally, the flexible carrier layer can be configured to cover at least a portion of the tissue, and the micro-protrusions can be configured to mechanically interface with the tissue.
A61B 17/11 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour réaliser l'anastomoseBoutons pour anastomose
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/24 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci
A61B 5/388 - Études de la conduction nerveuse, p. ex. détection du potentiel d’action d’un nerf périphérique
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
VIRGINIA COMMONWEALTH UNIVERSITY (USA)
Inventeur(s)
Gartenhaus, Ronald, B.
Kellogg, Glen, E.
Kapadia, Bandish, B.
Kayastha, Forum, B.
Herrington, Noah, B.
Abrégé
The present disclosure is concerned with substituted triazole 4-carbohydrazide compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in, for example, the treatment of cancers such as sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
Chimeric recombinant proteins for the detection of infection by Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
43.
IMMUNOSTIMULATORY CYCLIC DI-NUCLEOTIDE DELIVERY SYSTEM COMPOSITIONS AND METHOD OF USE THEREOF
Provided herein are pH-responsive nanovaccines (NVs) that stimulate the immune system. The NVs comprise nano- or micro-particles to which CDN-modified i-motif DNA is attached. When endocytosed within a subject to whom they are delivered, the change in pH to an acidic environment cause the CDNs to be released from the NVs. The CDNs are STING (stimulator of interferon genes) agonists and after their release, they bind to and activate STING, a critical step in stimulating the immune system. The NVs are used e.g. for cancer immunotherapy, to treat viral infections and/or as vaccine adjuvants.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Borreliella Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
45.
LIQUID COMPOSITIONS CONTAINING S-NITROSOTHIOLS AND USES THEREOF
Liquid compositions containing at least one S-nitrosothiol (RSNO), such as S-nitroso-N- acetylpenicillamine (SNAP) and S -nitrosoglutathione (GSNO), and at least one alkanediol or alkanediol oligomer/polymer are provided. To modulate the rate of release of NO, metal ion chelators may be added to reduce RSNO reactivity or chemical catalysts of RSNO decomposition may be added to increase RSNO reactivity. To suppress formation of undesirable nitrogen oxide species such as NO2, bases or reducing agents may be added. Methods of delivering nitric oxide to a subject and treating respiratory diseases by administering the liquid compositions are also provided.
C08K 5/43 - Composés contenant du soufre lié à l'azote
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p. ex. de buses de jet
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
46.
FIRE-RESISTANT, FIRE RETARDANT AND/OR THERMAL INSULATION
An open cell foam, and particularly aerogels or other foams, having an inorganic, hydraded phase change material (PCM) embedded within pores or cells or a network within the foam have fire retardant, fire resistant and thermal insulating properties. These composite materials are preferably monolithic in character, and are mechanically robust allowing for example the attachment of nails or screws. With the PCM distributed throughout the open cell foam, the composite material has a wide array of applications including providing thermal, fire resistant, and fire retardant uses in battery containers, in automotives and other vehicles, etc.
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p. ex. par séchage du coagulum
C09K 5/14 - Substances solides, p. ex. pulvérulentes ou granuleuses
F16L 59/02 - Forme ou configuration de matériaux isolants, avec ou sans revêtement formant un tout avec les matériaux isolants
The invention features methods of treating a SARS-CoV-2 infection in a subject, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
An open cell foam, and particularly aerogels or other foams, having an inorganic, hydraded phase change material (PCM) embedded within pores or cells or a network within the foam have fire retardant, fire resistant and thermal insulating properties. These composite materials are preferably monolithic in character, and are mechanically robust allowing for example the attachment of nails or screws. With the PCM distributed throughout the open cell foam, the composite material has a wide array of applications including providing thermal, fire resistant, and fire retardant uses in battery containers, in automotives and other vehicles, etc.
C09K 5/06 - Substances qui subissent un changement d'état physique lors de leur utilisation le changement d'état se faisant par passage de l'état liquide à l'état solide, ou vice versa
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
B32B 5/18 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par le fait qu'une des couches contient un matériau sous forme de mousse ou essentiellement poreux
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p. ex. par séchage du coagulum
C08J 9/35 - Mousses composites, c.-à-d. mousses macromoléculaires continues qui contiennent des particules ou des fragments cellulaires discontinus
The invention features methods of treating glioblastoma in a subject, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
3 β-hydroxy-5-cholestenoic acid 3-sulfate (CA3S), a sulfated derivative of 3β-hydroxy-5-cholestenoic acid (CA), is provided. Both CA and CA3S have potent cholesterol and triglyceride lowering and anti-inflammatory activities. Methods of using CA and CA3S to lower lipids and prevent or treat inflammation-associated diseases are also provided.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
51.
NOVEL CHIMERIC MULTI-PROTEIN BASED RECOMBINANT VACCINE ANTIGENS FOR PREVENTION OF LYME DISEASE IN ANIMALS AND HUMANS
A vaccine formulation for humans or other mammals (including dogs, horses, and cats) is provided. The vaccine formulation includes two chimeric proteins designed to elicit antibodies that bind to several targets on the surface of Lyme disease spirochetes during their residence in ticks and in mammals, and act synergistically to kill the bacteria through both antibody-mediated complement dependent and complement-independent mechanisms.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/40 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire bactériens
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
52.
3D PRINTED MAGNETIC-INFUSED ORIGAMI PLATFORM FOR 3D CELL CULTURE
An origami-inspired 3D printed in vitro culture platform is fabricated using a ferrous or ferrous-ferric matrix, such as a FesCri NPs/cellulose acetate (CA), to provide a hinged scaffold in which cells can migrate under changing directions of gravity. The platform portions of the hinged scaffold enable the control of pre- and post-culture time before and after folding, allowing for the observation of planar cell migration in microchannels and vertical cell migration between the vertically aligned channels. Platform characterization demonstrated favorable surface morphology, wettability, appropriate compressive stiffness for cell proliferation, noticeably decreased degradation, and acceptable low iron toxicity. Optimizing foldability with varying scaffold architecture and concentration of magnetic particles allowed precise alignment between the top and bottom faces. By applying an external magnetic field, the magnetic property of the NPs allows for the scaffold's folding, enabling temporospatial dynamic cell culture proliferation and migration.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
B29C 64/20 - Appareil pour la fabrication additiveDétails ou accessoires à cet effet
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
Ursolic acid (UA) preparations and a self-nanoemulsifying drug delivery system (SNEDDS) composition containing at least one UA preparation selected from monopotassium ursolate (UAK), dipotassium ursolate (UAK2), monocholine ursolate (UAmC), dicholine ursolate (UAdC), pharmacological salts thereof, and mixtures thereof are provided. Methods for synthesizing UA preparations and delivering UA preparations to subjects in need thereof are also provided.
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
54.
3D-PRINTABLE ONE-PART CARBON PARTICLE ELASTOMER INK FOR APPLICATIONS SUCH AS HEALTH MONITORING
3D printable inks are disclosed which include one-part room temperature vulcanized (RTV) silicone and carbon particles such as carbon nanotubes (CNTs). Butyl acetate may be used as a solvent to disperse the CNTs in the silicone in the ink precursor. The one-part nature of the inks (i) enables to print without prior mixing and cures under ambient conditions; (ii) allows directly dispensing 100 μm resolution printability on nonpolar and polar substrates; and (iii) forms both self-supporting and high-aspect-ratio structures, key aspects in additive biomanufacturing that eliminate the need for sacrificial layers; and (iv) lends efficient, reproducible, and highly sensitive responses to various tensile and compressive stimuli. The high electrical and thermal conductivity of the CNT-silicone composite is further extended to facilitate use as a flexible and stretchable heating element, with applications in body temperature regulation, water distillation, and a dual temperature sensor and Joule heating source, for example.
Exemplary embodiments of the present disclosure can include, for example, an atomic force microscopy (AFM) system, including a cantilever(s), an optical pickup unit(s) (OPU(s)) including a laser positioned over the cantilever(s), and a power source providing noise with a noise level that is below 300 Picometers. The noise level of the power source can be below 200
Exemplary embodiments of the present disclosure can include, for example, an atomic force microscopy (AFM) system, including a cantilever(s), an optical pickup unit(s) (OPU(s)) including a laser positioned over the cantilever(s), and a power source providing noise with a noise level that is below 300 Picometers. The noise level of the power source can be below 200
Picometers. A digitizing arrangement can be included which can be associated with the OPU. The digitizing arrangement(s) can have a bandwidth of about 2 MHZ. The OPU(s) can have a detection bandwidth of at least 80 MHZ. The exemplary apparatus can be combined with a chemical protocol and statistical signal processing and image analysis procedures to map DNA at high speed and accuracy.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12Q 1/683 - Tests d’hybridation pour la détection de mutation ou de polymorphisme faisant intervenir des enzymes de restriction, p. ex. polymorphisme de longueur de fragment de resctriction
Analgesic compounds which bind to multiple opioid receptors are provided, e.g., they bind to both the mu opioid receptor (MOR) and the kappa opioid receptor (KOR). The compounds are effective in relieving pain without causing addiction, and thus have a low or no potential for abuse.
Dry powder inhalers (DPIs) and related platforms are disclosed with a passive cyclic loading mode of operation. Metering elements such as a powder shelf may be used to control the amount of powder that is aerosolized with each actuation. Advantages of the passive cyclic loading system include metering a consistent amount of powder for each actuation while protecting the powder in the reservoir from aggregate formation. A single device can accommodate a variable range of powder doses and aerosolize a relatively consistent amount of dose with each actuation, while remaining insensitive to the amount of powder loaded (above a certain threshold).
A61M 11/02 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression d'air sur les liquides à pulvériser ou vaporiser
A combined flossing and interproximal brushing dental device, comprising: a handle having a proximal end and a distal end, wherein the proximal end is configured to be held by a user; a first arm; a second arm; dental floss engaging members positioned at or towards a free end of the first arm and at or towards a free end of the second arm, wherein said first arm and said second arm are spaced apart on the handle and the dental floss engaging members are configured to hold dental floss, extending between the first arm and the second arm; and an interproximal brush forming all or a part of the first arm.
A method for producing a purified morphinan-glycoside conjugate. The method includes the steps of contacting a morphinan compound with an activated saccharide or activated oligosaccharide and a glycosyltransferase in a reaction mixture under conditions, including any co-factors necessary for glycosyltransferase activity, effective to produce a morphinan-glycoside conjugate; and purifying the morphinan-glycoside conjugate from the reaction mixture to obtain the isolated morphinan-glycoside conjugate. Compounds, compositions, conjugates, and methods for their use are also provided.
C12P 19/60 - Préparation d'O-glucosides, p. ex. glucosides avec un atome d'oxygène du radical saccharide lié directement à un hétérocycle autre que saccharide ou à un système cyclique condensé contenant un hétérocycle autre que saccharide, p. ex. coumermycine, novobiocine
C07H 17/00 - Composés contenant des radicaux hétérocycliques liés directement à des hétéro-atomes de radicaux saccharide
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
Described herein are methods for preventing a relapse of cancer in a subject. The methods involve administering to the subject in need thereof a sulfated glycosaminoglycan or the pharmaceutically acceptable salt or ester thereof. In one aspect, the methods described herein prevent the growth or self-renewal of cancer stem cells in a subject. In another aspect, the methods described herein kill active or dormant cancer stem cells in a subject. The methods described herein can be used in combination with chemotherapy and/or radiation. The methods described herein are versatile with respect to preventing the relapse of a number of different cancers.
Provided herein is a copper-free, non-toxic click hydrogel that exhibits minimal swelling. The hydrogel may be used as a sealant and/or as a delivery vehicle for local administration of substances of interest, such as therapeutic agents.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/14 - Peptides contenant des radicaux saccharideLeurs dérivés
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
Polymeric drugs for disease therapy are provided. The repeat units of the polymers comprise at least one chemotherapeutic agent, e.g. a cancer drug. The linkages between repeat units are hydrolysable under physiological conditions, e.g. at targeted sites in vivo. Nanoparticles formed from the polymers are also provided.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes
64.
CLICK CHEMISTRY HYDROGEL WITH MINIMAL SWELLING AS A LOCAL DELIVERY VEHICLE
Provided herein is a copper-free, non-toxic click hydrogel that exhibits minimal swelling and derived from dibenzocyclooctyne maleimide, poly-ethylene glycol dithiol and azide acrylate. The hydrogel may be used as a sealant and/or as a delivery vehicle for local administration of substances of interest, such as therapeutic agents.
A61K 31/78 - Polymères contenant de l'oxygène d'acide acrylique ou de ses dérivés
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
C07C 13/547 - Hydrocarbures polycycliques ou leurs dérivés hydrocarbonés acycliques à cycles condensés à trois cycles condensés un cycle au moins n'étant pas un cycle à six chaînons, les autres cycles étant au plus des cycles à six chaînons
65.
RECOGNIZING FREEZING OF GAIT AND DEPLOYING VIBRATION TO MITIGATE SYMPTOMS
Various embodiments of the present disclosure are directed to systems and methods of utilizing a convolutional neural network to detect freezing of gait in patients and provide vibration to return to normal motor function. A system can perform a method of training a convolutional neural network by receiving a video recording; receiving a plurality of timestamp selections indicating when the person demonstrates a freezing of gait event during the video; receiving movement data from the sensing device; extracting domain data from the movement data; providing the plurality of domain data to the convolutional neural network; and deploying the convolutional neural network on a client device. Additionally, a system can be arranged to perform a method of receiving movement data from the sensing device; determining a categorization of the movement by processing the movement data through a convolutional neural network; and directing a vibration delivery device to deliver vibration.
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
A filter having antibacterial activity is provided. The filter comprises at least one layer of polymer nanofibers and antibacterial particles positioned on or within the at least one layer of polymer nanofibers, wherein the antibacterial particles comprise a quaternary ammonium compound grafted onto a surface of a metal-organic framework. Methods of manufacturing the filter and decontaminating a fluid are also provided.
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A01N 25/08 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des solides comme supports ou diluants
B01D 39/20 - Autres substances filtrantes autoportantes en substance inorganique, p. ex. papier d'amiante ou substance filtrante métallique faite de fils métalliques non-tissés
67.
USE OF MICRORNA INHIBITION TO PREVENT AND TREAT OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES
Inflammatory processes, particularly those arising from trauma or injury to the region of a bone joint, are causative of osteoarthritis (OA). A composition comprising microRNA-122, microRNA-122 mimic, and/or an inhibitor of microRNA-451 reduces or inhibits inflammatory mediators in articular chondrocytes and related cells. When administered to a subject at risk of developing OA, development of OA and/or progression of OA disease are inhibited, and cartilaginous structures are preserved in the joint. Since joint injury is associated with subsequent development of OA, the treatment is particularly suitable following an acute injury to a joint.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
Provided herein are methods for fluid resuscitation of an organ donor. The method includes administering intravenously to the organ donor an organ protectant solution comprising polyethylene glycol polymers (PEG) with a molecular weight of 18,000-40,000 Da at a concentration of 5-15% w/v. The methods are suitable for protecting organs prior to transplantation.
Provided herein are compositions containing guest/host inclusion complexes. In particular, each complex includes S-nitrosoglutathione (GSNO) as the guest and substituted or unsubstituted cyclodextrin as the host, such as alpha cyclodextrin. The compositions may be used as an antibacterial and antithrombotic agent in catheter lock solutions and to deliver nitric oxide to a subject in need thereof.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Disclosed herein are systems and methods for anomaly detection. A distributed physical state estimation system determines low-level state estimates covering respective sections of a cyber-physical system based on raw, high-performance measurement data. Low-level state estimates may be determined for a plurality of sections (substations) concurrently. An upper-level state estimate may be derived from the low-level state estimates. Anomalies pertaining to the system may be detected through analysis of the low-level and upper-level state estimates. The anomalies may be analyzed to determined whether the system is exhibiting behavior indicative of a fault, cyber-attack, and/or compromise.
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
G06F 11/07 - Réaction à l'apparition d'un défaut, p. ex. tolérance de certains défauts
G06F 11/34 - Enregistrement ou évaluation statistique de l'activité du calculateur, p. ex. des interruptions ou des opérations d'entrée–sortie
G06F 21/71 - Protection de composants spécifiques internes ou périphériques, où la protection d'un composant mène à la protection de tout le calculateur pour assurer la sécurité du calcul ou du traitement de l’information
G01R 21/133 - Dispositions pour procéder aux mesures de la puissance ou du facteur de puissance en utilisant des techniques numériques
Composite materials for simultaneous thermal management and electromagnetic interference screening of radiofrequency-based electronic systems are provided. The materials contain a phase change material and one or more electrically and thermally conductive filler particles. The materials provide a passive system for thermal management and EMI shielding that is lightweight, does not contain moving parts, and does not require an external power supply.
C04B 35/622 - Procédés de mise en formeTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques
C04B 35/01 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes
H01C 7/04 - Résistances fixes constituées par une ou plusieurs couches ou revêtementsRésistances fixes constituées de matériaux conducteurs en poudre ou de matériaux semi-conducteurs en poudre avec ou sans matériaux isolants à coefficient de température négatif
A method for treating a subject suffering from chronic multisystem illness, specifically gulf war illness, includes administering to the subject a therapeutically effective amount of a selective inhibitor of solTNF, whereby the subject is treated. In some embodiments, the selective inhibitor of solTNF includes a DN-TNF protein variant and/or a nucleic acid encoding the DN-TNF protein variant. In some embodiments, the DN-TNF protein variant includes XPro1595.
Provided are methods of treating cognitive impairment in a subject suffering from cirrhosis, comprising administering to the subject a therapeutically effective amount of albumin, wherein the subject does not currently suffer from overt hepatic encephalopathy. In particular, the subject has not suffered from overt hepatic encephalopathy within one month of the administering step. The albumin may be administered intravenously.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Brown, James E.
Theeuwes, Felix
Abrégé
Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia. In some cases, the at least one inflammatory condition is associated with Epstein-Ban virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
75.
FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER
Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano/microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.
A self-cleaning face covering is provided. The face covering includes a fabric layer having a resisitive heating element disposed on the fabric; and an infrared reflective layer arranged between the fabric layer and an inner surface of the face covering configured to reduce heat transfer to the inner surface. Methods of cleaning the face covering are also provided.
A41D 13/11 - Masques de protection du visage, p. ex. pour utilisation chirurgicale ou pour utilisation en atmosphère polluée
A61L 2/04 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques de la chaleur
A41D 13/005 - Vêtements protecteurs de travail ou de sport, p. ex. blouses de chirurgien ou vêtements protégeant des coups ou des chocs avec des conditions d'environnement interne qui sont commandées avec une température commandée
77.
A FACTOR H BINDING PROTEIN B (FHBB) BASED CHIMERIC VACCINE FOR THE PREVENTION AND TREATMENT OF PERIODONTAL DISEASE
Provided herein are recombinant Factor H Binding Protein B (FhbB) chimeric proteins comprising several different mutant variants of the Treponema denticola Factor H binding protein B (FhbB). The mutant variants cannot bind Factor H. The chimeric proteins are used to vaccinate subjects against periodontal disease either systemically and/or by direct application of antibodies generated against the chimeric proteins to the oral cavity (e.g. the gums) of a patient to prevent and/or treat periodontal disease.
Disclosed are various embodiments for training physicians to perform surgeries or procedures. To do this, a display can render a three-dimensional model of human anatomy and a virtual surgical instrument in a virtual space. A computing device can receive movement input from an input device. Based on the movement input from the input device, the computing device can cause the virtual surgical instrument to move on the display. The computing device can detect a collision between the virtual surgical instrument and the three-dimensional model of human anatomy in the virtual space and, in response, the computing device can direct the input device to provide haptic feedback. Various other features are disclosed that further aid in the training of a surgeon to perform surgeries or procedures.
Examples include spatially positioning, in a three-dimensional (3D) space, a conductive coil and a living subject in a 3D spatial relation in which a target 3D region of the living subject's tissue is within a designated 3D electric field formation region for the conductive coil. An energizing source feeds a low frequency (LF) modulated high frequency (HF) carrier voltage to terminals of the conductive coil. This urges a corresponding LF modulated HF coil current, of maximum magnitude MA, through the conductive coil. The HF frequency of the HF coil current produces a magnetic flux with a corresponding HF related rate of change. Optionally, a secondary coil feeds an unmodulated HF signal that spatially overlaps the modulated HF signals.
A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants
80.
MICRODEVICES AND PROCESSES TO SEPARATE AND PROCESS MIXED FORENSIC BIOLOGICAL SAMPLES
Microdevices and methods provide for separating cells of a single type from a mixed biological sample containing multiple types of cells. A single microdevice may be configured to allow for separating out cells into multiple groupings, each grouping containing cells of only one cell type. Transfer of separated cells off the microdevice is performed by physical separation of part of the microdevice from a remainder of the microdevice. This step advantageously minimizes accidental cell losses in the transfer. Subsequent analysis may then be performed using non-microfluidic equipment and techniques.
NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, acute myocardial infarction, heart failure, arthritis, diabetes, gout, COVID-19, and autoinflammatory diseases.
C07D 231/02 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles
C07D 233/02 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Devices to detect analytes (e.g., charged species such as ions) in samples are provided as are methods for their use. The devices comprise a tube or container comprising a water-immiscible sensing oil phase comprising at least one sensing chemical that binds the at least one analyte. The tube further receives an aqueous sample. Upon mixing of the two immiscible phases, the analyte partitions into the oil phase and binds to the sensing chemical, delectably changing the optical properties of the sensing chemical (or of an associated reporter molecule). Detection of the changes permits quantification of the amount or concentration of analyte in the sample without optical interference from the sample. The devices are suitable for home use and other decentralized settings.
In an example method for detecting indole, an indole producing bacterium, or an indole producing chemical, a polymeric detection tool is exposed to a sample and the polymeric detection tool is monitored for a red color change. The polymeric detection tool includes an acidic and oxygen soluble polymer and a nitrosation agent impregnated in walls of the acidic and oxygen soluble polymer. This example method can be used for detecting an indole producing bacterium in a body fluid sample.
A61L 29/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
C08J 7/06 - Revêtement par des compositions ne contenant pas de substances macromoléculaires
Containment units, dry powder inhalers, delivery systems, and methods for the same are disclosed. Exemplary devices are configured to have inlets and outlets which are formed with the containment walls of a containment unit. Air jets formed by the configuration of inlet(s) and outlet(s) inside the containment unit create significant turbulence and deaggregate the powder. Delivery system components downstream of the containment unit may integrate the exiting aerosol plume with a low flow nasal cannula air stream for delivery to a subject.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Abrégé
Aspects of the present disclosure include methods for treating at least one autoimmune condition, such as at least one of hepatitis, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. In some cases, the at least one autoimmune condition is associated with Epstein-Barr virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
Provided are a Native Cell Membrane Nanoparticle (NCMN) system and methods of using the NCMN polymers to extract and/or purify one or more membrane proteins. The NCMN system includes at least one NCMN polymer and one or more membrane proteins in their native lipid bilayer membrane. A method of using the NCMN system to extract or isolate the one or more membrane proteins in the form of NCMN system without the use of a detergent while maintaining the protein’s native structure and functional activity is provided.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Brown, James E.
Blaschke, Terrence
Abrégé
Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25- hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27- hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24- hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
89.
AEROSOL-ASSISTED SYNTHESIS OF CRYSTALLINE TUNGSTEN BRONZE PARTICLES
Provided herein are methods for producing crystalline tungsten bronze oxide particles. The method may include atomizing a liquid solution comprising an alkali metal precursor and a tungsten precursor to produce droplets; mixing the droplets with one or more gaseous flows to produce a combined flow; flowing the combined flow through a heated reactor to provide crystalline tungsten bronze oxide particles having the formula MxWO3, wherein M is the alkali metal; and collecting the particles.
A series of non-peptide opioid receptor modulators having the general formula: (I) is provided. In the formula: R = (II) * is a chiral carbon; M is a saturated or unsaturated, branched or unbranched, substituted or unsubstituted alkyl chain from 0-10 atoms in length; X1, X2, X3, X4, or X5 are independently, C, N, O, or S; and R is attached to M by any of X1, X2, X3, X4, or X5. The compounds are used to treat disorders related to opioid receptor functions such as opioid addiction, opioid overdose, pain and constipation caused by opioid use.
Provided are systems and methods of identifying the functional characteristics and operational settings of any electronic inhalants or apparatuses that are designed to provide nicotine vapors to a user. The system includes a mobile device having a built-in camera to receive images of a nicotine delivery device, a system of remote backend servers with at least one image database for identifying the nicotine delivery device, and at least one processor for calculating an amount of nicotine delivered by the nicotine delivery device.
Methods for detecting length polymorphisms in a DNA sample are provided. The methods include steps of amplifying a target region of the DNA in the sample, wherein the DNA sample is diluted prior to the amplifying step to provide a plurality of amplified samples in which 0 or 1 target DNA strand is amplified in each amplified sample and wherein at least one amplified sample includes 1 target DNA strand; depositing the plurality of amplified samples onto a surface; imaging the plurality of amplified samples deposited on the surface using atomic force microscopy (AFM) to determine an amplicon length distribution; comparing the amplicon length distribution to a corresponding amplicon length distribution obtained from a reference DNA sample that does not contain a length polymorphism in the target region; and detecting a length polymorphism in the target region of the DNA sample when the amplicon length distribution is distinct from the corresponding amplicon length distribution.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Low-cost and earth abundant, Ni1−xMox alloy nanocrystals, with sizes ranging from 18-43 nm and varying Mo composition (0.0-11.4%), were produced by a colloidal chemistry method for alkaline HER reactions. For a water splitting current density of ˜10 mA/cm2, these alloys demonstrate over-potentials of −62 to −177 mV, which are comparable to commercial Pt-based electrocatalysts (−68 to −129 mV). The cubic Ni0.934Mo0.066 alloy nanocrystals exhibit the highest activity as alkaline HER electrocatalysts, outperforming commercial Pt/C (20 wt %) catalyst.
C22C 19/03 - Alliages à base de nickel ou de cobalt, seuls ou ensemble à base de nickel
B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensionsAppareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p. ex. de solutions
A method of delivering an active ingredient to a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a formulation comprising biodegradable, polymeric microparticles and an active ingredient selected from the group consisting of levo-alpha-acetylmethadol (LAAM), nor-LAAM, and dinor-LAAM, wherein the active ingredient is part of a hydrophobic ion-pairing (HIP) complex and wherein the HIP complex is associated with the microparticles. Sustained release formulations containing an active ingredient are also provided.
A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
95.
USE OF OXYGENATED CHOLESTEROL SULFATES FOR CANCERS AND NON-CANCEROUS TRANSFORMATIONS RELATED TO EPSTEIN-BARR VIRUS
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Abrégé
Aspects of the present disclosure include methods for treating at least one of cancer and non-cancerous transformation related to Epstein-Barr virus, such as at least one of Hodgkin's lymphoma, soft tissue sarcoma, leiomyosarcoma, nasopharyngeal carcinoma, Burkitt's lymphoma, T-cell lymphoma, gastric carcinoma, invasive breast cancer, and hierarchically organized carcinoma. Hierarchically organized carcinomas include, but are not limited to, pancreatic ductal adenocarcinoma, urothelial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, esophagus cancer, breast cancer, thyroid cancer, oral cancer, cervical cancer, ovarian cancer, and liver cancer. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
Provided are stimulation devices for improving ambulatory activity of a subject in need thereof. The device includes a foot covering for holding two battery-operated tactile actuators on a metatarsal region and an ankle region of the wearer's foot. The foot covering also includes a detachable material for housing and securing the two tactile actuators and a pouch region for holding electronics.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61H 23/02 - Massage par percussion ou vibration, p. ex. en utilisant une vibration ultrasoniqueMassage par succion-vibrationMassage avec des membranes mobiles à entraînement électrique ou magnétique
97.
USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES, AND ADDICTION
THE UNITED STATE GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Brown, James E.
Theeuwes, Felix
Abrégé
Aspects of the present disclosure include methods for treating at least one of depression, neurodegenerative disease, multiple sclerosis, Parkinson's disease, spinocerebellar degeneration, Friedreich ataxia, ataxia-telangiectasia, progressive supranuclear palsy, Huntington's disease, striatonigral degeneration, olivopontocerebellar atrophy, Shy-Drager syndrome, schizophrenia, schizoaffective disorder, manic-depression (bipolar) disorder, disturbed or abnormal circadian entrainment, childhood Alice in Wonderland syndrome, childhood acute cerebellar ataxia, and Alzheimer's disease. In some instances, methods include treating an addiction to a drug, such as alcohol addiction, cocaine addiction or amphetamine addiction. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
Disclosed are various approaches for generating synthetic computer tomography (CT) images using magnetic resonance imaging A patient body outline (PBO) of a patient is obtained. Then, a magnetic resonance image set in a limited field of view (MRI-in-LFOV) of the patient is converted into a synthetic computed tomography (CT) image set in limited field of view (syn-CT-in-LFOV) of the patient. Next, the syn-CT-in-LFOV is expanded to a synthetic CT image set in full field of view (syn-CT-in-FFOV) of the patient based at least in part on the PBO.
G06T 11/60 - Édition de figures et de texteCombinaison de figures ou de texte
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
99.
METHODS FOR DECELLULARIZING ANIMAL TISSUE AND BIOINKS DERIVED THEREFROM
